Literature DB >> 7143205

Disposition and absolute bioavailability of furosemide in healthy males.

E S Waller, S F Hamilton, J W Massarella, M A Sharanevych, R V Smith, G J Yakatan, J T Doluisio.   

Abstract

Furosemide (40 mg) was administered to 18 healthy adult males as an intravenous dose, an oral solution, and in tablet form. The pharmacokinetics of intravenous furosemide were studied, determining a total body clearance rate of 117.6 +/- 41.3 ml/min and a harmonic mean half-life of 78 min. The mean absolute bioavailability determined by ratio of areas under the plasma-time curves was 64 and 71% for the solution and tablet, respectively. The mean absolute bioavailability determined by the ratio of urinary cumulative excretion data was 61 and 66% for the solution and tablet, respectively. The absolute bioavailability of furosemide determined with plasma and urine data were not significantly different. Thus, urine data alone may be used to establish bioavailability of furosemide. Inspection of plasma-time curves revealed secondary maxima in several subjects, suggesting enterohepatic cycling.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7143205     DOI: 10.1002/jps.2600711006

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

3.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.

Authors:  T Li; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

5.  Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.

Authors:  H Ogata; Y Kawatsu; Y Maruyama; K Machida; T Haga
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Implications of intraindividual variability in bioavailability studies of furosemide.

Authors:  A Grahnén; M Hammarlund; T Lundqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

Review 8.  Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Authors:  Siavosh Naji-Talakar; Sheena Sharma; Leslie A Martin; Derek Barnhart; Bhagwat Prasad
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

Review 9.  Nephrotic Syndrome: Oedema Formation and Its Treatment With Diuretics.

Authors:  Sanjana Gupta; Ruth J Pepper; Neil Ashman; Stephen B Walsh
Journal:  Front Physiol       Date:  2019-01-15       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.